

PHARMACEUTICAL TURNOVER
Three months ended 31st March 2006

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,309	4	9	670	4	13	424	3	2	215	4	13
<i>Seretide/Advair</i>	816	12	18	460	11	21	276	11	10	80	20	36
<i>Flixotide/Flovent</i>	178	10	16	86	30	41	47	(4)	(4)	45	(2)	2
<i>Serevent</i>	74	(9)	(6)	23	(13)	(4)	36	(10)	(10)	15	-	-
<i>Flixonase/Flonase</i>	131	(27)	(23)	94	(27)	(22)	13	(7)	(7)	24	(38)	(35)
CENTRAL NERVOUS	896	11	18	623	19	30	164	(10)	(11)	109	9	14
<i>Seroxat/Paxil</i>	161	(4)	(1)	53	(4)	6	41	(21)	(21)	67	10	10
<i>Paxil IR</i>	110	(11)	(10)	6	(55)	(45)	41	(21)	(21)	63	7	7
<i>Paxil CR</i>	51	15	24	47	10	21	-	-	-	4	100	100
<i>Wellbutrin</i>	217	22	33	213	23	33	1	-	-	3	(33)	-
<i>Wellbutrin IR, SR</i>	24	(31)	(25)	21	(33)	(30)	1	-	-	2	(50)	-
<i>Wellbutrin XL</i>	193	35	47	192	35	48	-	-	-	1	-	-
<i>Imigran/Imitrex</i>	182	2	9	135	-	10	37	12	12	10	(9)	(9)
<i>Lamictal</i>	237	14	22	174	33	45	48	(22)	(24)	15	8	25
<i>Requip</i>	58	83	93	37	>100	>100	19	27	27	2	-	-
ANTI-VIRALS	699	10	16	338	3	12	209	14	12	152	22	31
HIV	399	4	10	182	(5)	2	163	14	13	54	12	32
<i>Combivir</i>	143	(3)	2	62	(16)	(9)	59	5	5	22	25	38
<i>Trizivir</i>	72	(7)	(3)	37	(13)	(5)	32	3	3	3	(25)	(25)
<i>Epivir</i>	60	(12)	(9)	20	(24)	(20)	26	(10)	(13)	14	9	27
<i>Ziagen</i>	32	(9)	(3)	13	(8)	-	11	(21)	(21)	8	17	33
<i>Agenerase, Lexiva</i>	33	41	50	19	29	36	12	71	71	2	-	100
<i>Epzicom/Kivexa</i>	51	>100	>100	29	80	93	19	>100	>100	3	-	-
Herpes	236	13	20	145	17	27	36	3	-	55	11	17
<i>Valtrex</i>	204	16	24	143	17	28	26	8	4	35	22	30
<i>Zovirax</i>	32	(6)	(3)	2	-	-	10	(9)	(9)	20	(5)	-
<i>Zeffix</i>	38	24	31	3	-	-	5	25	25	30	27	36
METABOLIC	434	26	36	295	26	37	58	45	45	81	17	27
<i>Avandia</i>	344	30	42	265	34	46	32	23	23	47	17	31
<i>Avandamet</i>	28	(39)	(36)	4	(88)	(88)	19	>100	>100	5	-	25
<i>Avandaryl</i>	12	-	-	12	-	-	-	-	-	-	-	-
<i>Bonviva/Boniva</i>	15	-	-	14	-	-	1	-	-	-	-	-
VACCINES	366	44	48	83	41	54	165	46	45	118	41	48
<i>Hepatitis</i>	116	18	23	37	27	42	55	17	15	24	10	20
<i>Infanrix/Pediarix</i>	124	54	59	41	32	46	68	73	70	15	40	50
<i>Boostrix</i>	10	>100	>100	5	-	-	3	>100	>100	2	>100	100
CARDIOVASCULAR AND UROGENITAL	426	29	37	294	53	67	96	(6)	(7)	36	10	16
<i>Coreg</i>	225	53	67	224	54	68	-	-	-	1	(50)	(50)
<i>Levitra</i>	11	-	10	10	-	11	-	-	-	1	-	-
<i>Avodart</i>	47	73	81	28	>100	>100	16	42	33	3	-	50
<i>Arixtra</i>	11	>100	>100	7	>100	>100	4	100	100	-	-	-
<i>Fraxiparine</i>	51	(4)	(2)	-	-	-	44	-	(2)	7	(29)	-
ANTI-BACTERIALS	378	(12)	(9)	62	(25)	(18)	180	(18)	(19)	136	7	14
<i>Augmentin</i>	170	(14)	(11)	31	(38)	(34)	83	(15)	(15)	56	13	19
<i>Zinnat/Ceftin</i>	50	(23)	(19)	4	33	33	26	(38)	(38)	20	6	18
ONCOLOGY AND EMESIS	288	14	23	225	20	32	41	(5)	(5)	22	-	5
<i>Zofran</i>	230	13	22	181	19	30	30	(6)	(9)	19	(6)	12
<i>Hycamtin</i>	29	8	16	20	6	18	7	14	-	2	-	100
OTHER	249	(6)	(1)	25	35	47	58	(30)	(28)	166	2	8
<i>Zantac</i>	65	7	10	21	54	62	14	(6)	(13)	30	(7)	-
	5,045	10	16	2,615	15	26	1,395	1	1	1,035	12	19

Pharmaceutical turnover includes co-promotion income.

INCOME STATEMENT
Three months ended 31st March 2006

	Q1 2006 £m	Q1 2005 £m	Growth CER%	£%
Turnover:				
Pharmaceuticals	5,045	4,339	10	16
Consumer Healthcare	768	697	6	10
TURNOVER	5,813	5,036	10	15
Cost of sales	(1,134)	(1,127)	(2)	1
Gross profit	4,679	3,909	13	20
Selling, general and administration	(1,823)	(1,645)	5	11
Research and development	(753)	(663)	10	14
Other operating income	71	146		
Operating profit:				
Pharmaceuticals	2,034	1,626	16	25
Consumer Healthcare	140	121	11	16
OPERATING PROFIT	2,174	1,747	15	24
Finance income	73	49		
Finance expense	(92)	(98)		
Share of after tax profits of associates and joint ventures	15	13		
PROFIT BEFORE TAXATION	2,170	1,711	17	27
Taxation	(640)	(488)		
<i>Tax rate %</i>	29.5%	28.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,530	1,223	16	25
Profit attributable to minority interests	28	21		
Profit attributable to shareholders	1,502	1,202		
	1,530	1,223		
EARNINGS PER SHARE	26.5p	21.1p	17	26
Diluted earnings per share	26.3p	21.0p		

CONSUMER HEALTHCARE TURNOVER
Three months ended 31st March 2006

	£m	Growth CER%	£%
Over-the-counter medicines	374	3	9
Analgesics	95	7	13
Dermatological	40	(3)	3
Gastrointestinal	65	2	12
Respiratory tract	41	8	8
Smoking control	93	5	12
Natural wellness support	34	-	3
Oral care	242	7	11
Nutritional healthcare	152	10	13
Total	768	6	10